Quantcast

Latest Angiogenesis inhibitors Stories

2014-01-22 12:26:53

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need RemainsMacular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains SummaryGBI Research has released its research, "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 -...

2014-01-03 15:47:18

A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA). The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer. But research published today in the American Heart Association’s journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of...

2013-10-03 09:31:58

The phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumor growth, prolonging survival of patients with advanced gastric cancer This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10...

2013-06-03 10:48:37

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting. GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the...

2013-06-03 10:45:11

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center. The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related